Status:
COMPLETED
Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
Lead Sponsor:
Central Institute of Mental Health, Mannheim
Conditions:
Psychotic Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders
Detailed Description
Major depressive episodes (MDE) frequently occur during the course of schizophrenic psychoses, both as as "post-psychotic" depressions, and also independently from psychotic episodes. A number of clin...
Eligibility Criteria
Inclusion
- Major depressive episode, Severity: CDSS at least 8 points or HAMD at least 15 points, indication for the treatment with duloxetine
- Lifetime diagnosis of a psychotic disorder (PANSS positive scale below 15 points)
- Age between 18 and 65,
- Informed consent
Exclusion
- No informed consent,
- Contraindications with respect to duloxetine,
- Gravidity or missing anticonceptive safety
- Substance dependance (excluded nicotin)
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00224302
Start Date
August 1 2005
End Date
November 1 2007
Last Update
June 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Institute of Mental Health, Department of Psychiatry,
Mannheim, Baden-Wurttemberg, Germany, 68159